Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Drug trial updates in multiple myeloma and SMM

Enrique Ocio • 2 Jun 2019
ASCO 2019
Multiple Myeloma Carfilzomib Daratumumab Dexamethasone Isatuximab Lenalidomide

Enrique Ocio, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain gives an overview of key drug trials for multiple myeloma and smoldering multiple myeloma (SMM). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Enrique Ocio

2:18
Efficacy and safety results from the ANCHOR trial
Enrique Ocio • 29 Sep 2023
2:03
The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMM
Enrique Ocio • 29 Sep 2023
1:27
Clonal hematopoiesis in multiple myeloma and implications for therapy
Enrique Ocio • 29 Sep 2023
Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals